Pegcrisantaspase

Phase 3Protein / enzyme

Pegcrisantaspase is one of 96 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Lymphoblastic LeukemiaActive, not recruiting

Atopic DermatitisActive, not recruiting

B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Atopic DermatitisPhase 3

Active, not recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

11 2

Daliresp

AstraZeneca

Phase 3

4 3

Cytosar

Teva

Phase 3

1 4

Amlitelimab

Sanofi

Phase 3

6 5

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 6

Calcineurin Inhibitors

Sanofi

Phase 3

1 7

Broncho-Vaxom

OOM Pharma SA

Phase 3

1 8

Pegcrisantaspase

Jazz Pharmaceuticals

Phase 3

1 9

EBGLYSS

Cibinqo

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Atopic Dermatitis

NCT04526795

Q2 2028

Phase 2Recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT04546399

Clinical

Trials by Indication[1]

B-cell acute lymphoblastic leukemia1 trial

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04546399·461 enrolled

Acute Lymphoblastic Leukemia1 trial

A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)

Terminated· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT02257684·4 enrolled

Atopic Dermatitis1 trial

DIMPLE: Nemolizumab in Moderate-to-Severe AD

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT04526795·680 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pegcrisantaspase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pegcrisantaspase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pegcrisantaspase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: Jazz Pharmaceuticals

Pegcrisantaspase

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Trials by Indication[1]

B-cell acute lymphoblastic leukemia1 trial

Acute Lymphoblastic Leukemia1 trial

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News